Pegylated OXM variants

• US 9,821,070 B2
• Filed: 01/08/2015
• Issued: 11/21/2017
• Est. Priority Date: 06/04/2012
• Status: Active Grant

• Current Assignee: Opko Biologics Ltd. (Opko Health, Inc.)
• Original Assignee: Opko Biologics Ltd. (Opko Health, Inc.)
• Inventors: Fima, Udi Eyal, Hershkovitz, Oren
• Primary Examiner(s): Ha, Julie
• Assistant Examiner(s): Hellman, Kristina M
• Application Number:
  US14/592,641
• Publication Number:
  US 20150119320A1
• Time in Patent Office: 1,048 Days
• Field of Search: None
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 1/00 General methods for the preparation of peptides , i.e. processes for the organic chemical preparation of peptides or proteins of any length
• CPC Class Codes: C07K 14/605 Glucagons

Abstract

A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.

Claims

1. A homogeneous conjugate represented by the structure of:

2. The homogeneous conjugate of claim 1, wherein said PEG is represented by (CH₂CH₂O)_nCH₃, wherein n is 30 (PEG30), 40 (PEG40) or 60 (PEG60).

3. The homogeneous conjugate of claim 1, wherein said pharmaceutically acceptable salt is a TFA salt, an HCl salt, or an acetate salt.

4. A pharmaceutical composition comprising the conjugate of claim 1, and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4, wherein said PEG is represented by (CH₂CH₂O)_nCH₃, wherein n is 30 (PEG30), 40 (PEG40) or 60 (PEG60).

6. A method of reducing food intake comprising administering to a subject in need thereof the composition of claim 4.

7. A method of treating obesity comprising administering to a subject in need thereof the composition of claim 4.

8. A method of reducing body weight comprising administering to a subject in need thereof the composition of claim 4.

9. A method of increasing energy expenditure comprising administering to a subject in need thereof the composition of claim 4.

10. A method of reducing food intake comprising administering to a subject in need thereof the conjugate of claim 1.

11. A method of treating obesity comprising administering to a subject in need thereof the conjugate of claim 1.

12. A method of reducing body weight comprising administering to a subject in need thereof the conjugate of claim 1.

13. A method of increasing energy expenditure comprising administering to a subject in need thereof the conjugate of claim 1.